Search

Author/Creator Gorlia, T

1. OS05.2.A MGMT promoter status in IDH1/2 mutant anaplastic astrocytoma patients assessed by DNA methylation profiling and qMS-PCR: a report from the EORTC Brain Tumor Group. (9th September 2021)

Authors:
Tesileanu, C M S; French, P J; Sanson, M; Brandes, A A; Wick, W; Clement, P M; Kros, J M; Gorlia, T; Golfinopoulos, V; van den Bent, M J
Journal:
Neuro-oncology
Issue:
Volume 23: Supplement 2 (2021)
Page Start:
ii6
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. OS05.3.A Temporal muscle thickness as surrogate parameter of sarcopenia in newly diagnosed glioblastoma patients:translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials. (9th September 2021)

Authors:
Furtner, J; Weller, M; Weber, M; Gorlia, T; Nabors, B; Reardon, D; Tonn, J; Stupp, R; Preusser, M
Journal:
Neuro-oncology
Issue:
Volume 23: Supplement 2 (2021)
Page Start:
ii7
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. OS4.6 Does radiation target volume affect health-related quality of life in patients with low grade glioma on the short-term? - a secondary analysis of the EORTC 22033–26033 trial. (19th September 2018)

Authors:
Seidel, C; Dirven, L; Rejneveld, J C; Coens, C; Taphoorn, M J B; Gorlia, T; Tzuk-Shina, T; Back, M; Stupp, R; Baumert, B
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii223
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. OS7.2 Measuring change in health-related quality of life: the added value of analysis on the individual patient level in glioma patients in clinical decision making. (6th September 2019)

Authors:
Coomans, M; Taphoorn, M J B; Aaronson, N; Baumert, B G; van den Bent, M; Bottomley, A; Brandes, A A; Chinot, O; Coens, C; Gorlia, T; Herrlinger, U; Keime-Guibert, F; Malmström, A; Martinelli, F; Stupp, R; Talacchi, A; Weller, M; Wick, W; Reijneveld, J C; Dirven, L
Journal:
Neuro-oncology
Issue:
Volume 21(2019)Supplement 3
Page Start:
iii14
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. OS7.4 Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM). (6th September 2019)

Authors:
Coomans, M; Dirven, L; Bottomley, A; van den Bent, M; Sloan, J; Stupp, R; Weller, M; Reijneveld, J C; Taphoorn, M; Aaronson, N; Baumert, B G; Brandes, A A; Chinot, O; Coens, C; Gorlia, T; Herrlinger, U; Keime-Guibert, F; Malmström, A; Martinelli, F; Talacchi, A
Journal:
Neuro-oncology
Issue:
Volume 21(2019)Supplement 3
Page Start:
iii14
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P01.052 Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux -M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406). (19th September 2018)

Authors:
van den Bent, M; French, P; Eoli, M; Sepulvado, J; Walenkamp, A; Weller, M; Looman, J; Ansell, P; Gorlia, T; Golfinopoulos, V
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii241
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P01.066 Patients with EGFR amplification but without EGFRvIII expression have improved benefit compared to those with EGFRvIII expression in samples of the INTELLANCE 2/EORTC 1410 randomized phase II trial. (19th September 2018)

Authors:
French, P J; Kros, J; de Heer, I; Ansell, P; Looman, J; Bain, E; Morfouace, M; Gorlia, T; Golfinopoulos, V; van den Bent, M
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii244
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗